Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
St Louis, MO
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Albany, NY
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Buffalo, NY
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Cleveland, OH
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Austin, TX
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Tyler, TX
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated:  12/1/2015
mi
from
Buenos Aires,
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
A Randomized, Open-label Study Comparing Adjuvant Chemotherapy With Xeloda, or 5-fluorouracil Plus Leucovorin, on Disease-free and Overall Survival in Patients Who Have Had Surgery for Colon Cancer
Status: Enrolling
Updated: 12/1/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
A Phase II Randomized Controlled Clinical Trial Of The Antiestrogen GTx-006 In Subjects With Prostate Cancer
Status: Enrolling
Updated:  12/1/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
A Phase II Randomized Controlled Clinical Trial Of The Antiestrogen GTx-006 In Subjects With Prostate Cancer
Status: Enrolling
Updated: 12/1/2015
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
A Pilot Study to Examine the Association Between Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
Status: Enrolling
Updated:  12/1/2015
Duke Cancer Center
mi
from
Durham, NC
Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
A Pilot Study to Examine the Association Between Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer
Status: Enrolling
Updated: 12/1/2015
Duke Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer
Status: Enrolling
Updated:  12/2/2015
Arizona Oncology - Scottsdale
mi
from
Scottsdale, AZ
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer
Status: Enrolling
Updated: 12/2/2015
Arizona Oncology - Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Immune Response in Peripheral Blood of Patients With Colon Cancer
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Immune Response in Peripheral Blood of Patients With Colon Cancer
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Markers of Response to Intravesical Bladder Cancer Therapy
Markers of Response to Intravesical Bladder Cancer Therapy
Status: Enrolling
Updated:  12/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Markers of Response to Intravesical Bladder Cancer Therapy
Markers of Response to Intravesical Bladder Cancer Therapy
Status: Enrolling
Updated: 12/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Quantitative MR Biomarkers for Sarcoma Treatment
Quantitative MR Biomarkers for Sarcoma Treatment
Status: Enrolling
Updated:  12/2/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Quantitative MR Biomarkers for Sarcoma Treatment
Quantitative MR Biomarkers for Sarcoma Treatment
Status: Enrolling
Updated: 12/2/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated:  12/2/2015
Emory University Hospital
mi
from
Atlanta, GA
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated: 12/2/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated:  12/2/2015
The Emory Clinic
mi
from
Atlanta, GA
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases
Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Intra-axial Brain Metastases
Status: Enrolling
Updated: 12/2/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
Status: Enrolling
Updated:  12/2/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
Status: Enrolling
Updated: 12/2/2015
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
A Lifestyle Intervention for Breast Cancer Survivors
Targeting the Teachable Moment: A Lifestyle Intervention for Breast Cancer Survivors
Status: Enrolling
Updated:  12/2/2015
University of Connecticut
mi
from
Storrs, CT
A Lifestyle Intervention for Breast Cancer Survivors
Targeting the Teachable Moment: A Lifestyle Intervention for Breast Cancer Survivors
Status: Enrolling
Updated: 12/2/2015
University of Connecticut
mi
from
Storrs, CT
Click here to add this to my saved trials
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer
Feasibility of an Evidence-based Walking Program in a Sample of Men Age >65 Undergoing Treatment for Prostate Cancer
Status: Enrolling
Updated:  12/2/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer
Feasibility of an Evidence-based Walking Program in a Sample of Men Age >65 Undergoing Treatment for Prostate Cancer
Status: Enrolling
Updated: 12/2/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated:  12/2/2015
North Memorial Medical Center
mi
from
Minneapolis, MN
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated: 12/2/2015
North Memorial Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated:  12/2/2015
Fairview University
mi
from
Minneapolis, MN
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated: 12/2/2015
Fairview University
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated:  12/2/2015
Park Nicollet Institute
mi
from
St. Louis Park, MN
Predictors of Lymphedema Following Breast Cancer Surgery
Predictors of Lymphedema Following Breast Cancer Surgery
Status: Enrolling
Updated: 12/2/2015
Park Nicollet Institute
mi
from
St. Louis Park, MN
Click here to add this to my saved trials
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated:  12/2/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer
Status: Enrolling
Updated: 12/2/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer
The Molecular Effects of Nutrition Supplements (MENS) Prostate Study
Status: Enrolling
Updated:  12/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer
The Molecular Effects of Nutrition Supplements (MENS) Prostate Study
Status: Enrolling
Updated: 12/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North/University Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at UMC North
mi
from
Tucson, AZ
Click here to add this to my saved trials
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
Status: Enrolling
Updated:  12/3/2015
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
Status: Enrolling
Updated: 12/3/2015
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Stanford, CA
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Lafayette, IN
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Baltimore, MD
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Boston, MA
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Detroit, MI
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Detroit, MI
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Buffalo, NY
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
New York, NY
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors
Yoga Cancer Rehabilitation Study
Status: Enrolling
Updated:  12/3/2015
VA Boston Healthcare System Brockton Campus, Brockton, MA
mi
from
Brockton, MA
Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors
Yoga Cancer Rehabilitation Study
Status: Enrolling
Updated: 12/3/2015
VA Boston Healthcare System Brockton Campus, Brockton, MA
mi
from
Brockton, MA
Click here to add this to my saved trials
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149
Status: Enrolling
Updated:  12/3/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149
Status: Enrolling
Updated: 12/3/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
A Pilot Study on the Effects of Preoperative Physical Therapy in Adolescents and Young Adults Diagnosed With a Lower Extremity Malignancy
Status: Enrolling
Updated:  12/3/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
A Pilot Study on the Effects of Preoperative Physical Therapy in Adolescents and Young Adults Diagnosed With a Lower Extremity Malignancy
Status: Enrolling
Updated: 12/3/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
Nashville, TN
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.
Status: Enrolling
Updated:  12/3/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.
Status: Enrolling
Updated: 12/3/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.
Status: Enrolling
Updated:  12/3/2015
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Brussel,
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.
Status: Enrolling
Updated: 12/3/2015
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Brussel,
Click here to add this to my saved trials
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated:  12/3/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated: 12/3/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated:  12/3/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase I Clinical, Pharmacokinetic, And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991, A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Status: Enrolling
Updated: 12/3/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials